Lessons Learnt in the First Year of an Australian Pediatric Cardio Oncology Clinic

Author:

Toro Claudia1,Felmingham Ben1,Jhadav Mangesh2,Celermajer David S.3,Gerche Andre La4,O’Sullivan John5,Kumar Sanjeev6,Mateos Marion K.7,Fulbright Joy8,Govender Dinisha,Collier Lane1,Cheung Michael2,Eisenstat David2,Lange Peter W.9,Ayer Julian5,Elliott David A.1,Conyers Rachel1

Affiliation:

1. Murdoch Children's Research Institute

2. The Royal Children’s Hospital

3. RPA Hospital

4. Baker Heart and Diabetes Institute Commercial Road

5. The University of Sydney

6. Chris O’Brien Lifehouse

7. Kids Cancer Centre, Sydney Children’s Hospital Randwick

8. Children’s Mercy Kansas City

9. University of Melbourne

Abstract

Abstract Background: Modern oncological therapies together with chemotherapy and radiotherapy have broadened the agents that can cause cardiac sequelae, which can manifest for pediatric oncology patients while on active treatment. Recommendations for high-risk patients who should be monitored in a pediatric cardio-oncology clinic have previously been developed by expert Delphi consensus by our group. In 2022 we opened our first multidisciplinary pediatric cardio-oncology clinic adhering to these recommendations in surveillance and management. Objectives: Our pediatric cardio-oncology clinic aimed to: (i) Document cardiovascular toxicities observed within a pediatric cardio-oncology clinic and (ii) Evaluate the applicability of the Australian and New Zealand Pediatric Cardio-Oncology recommendations. Methods: Monthly multidisciplinary cardio-oncology clinics were conducted in an Australian tertiary pediatric hospital. Structured standardised approaches to assessment were built into the electronic medical record (EMR). All patients underwent baseline echocardiogram and electrocardiogram assessment together with vital signs in conjunction with standard history and examination. Results: Nineteen (54%) individuals had a documented cardiovascular toxicity or pre-existing risk factor prior to referral. The two most common cardiovascular toxicities documented during clinic review included Left Ventricular Dysfunction (LVD) and hypertension. Of note 3 (8.1%) patients had CTCAE grade III LVD. An additional 10 (27%) patients reviewed in clinic had CTCAE grade I hypertension. None of these patients had hypertension noted within their referral. Cascade testing for cardiac history was warranted in 2 (5.4%) of patients. Conclusions: Pediatric cardio-oncology clinics are likely beneficial to documenting previously unrecognised cardiotoxicity and relevant cardiac family histories, whilst providing an opportunity to address lifestyle risk factors.

Publisher

Research Square Platform LLC

Reference25 articles.

1. National Cancer Institute. D, Surveillance Research Program. SEER Cancer Statistics Review 1975–2016. 2019.

2. Chronic health conditions in adult survivors of childhood cancer;Oeffinger KC;N Engl J Med,2006

3. Cardio-Oncology Recommendations for Pediatric Oncology Patients;Toro C;JACC: Adv,2022

4. Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography;Lai WW;J Am Soc Echocardiogr,2006

5. Common Terminology. Criteria for Adverse Events (CTCAE) version 5.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3